AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 171 min read$TARS

Farrow Jeffrey S sold $877K of TARS

Farrow Jeffrey S (See Remarks) sold 14,396 shares of Tarsus Pharmaceuticals, Inc. (TARS) at $60.95 ($0.88M total) on 2026-06-16.

Original reporting
SEC EDGAR · Farrow Jeffrey S
Published Jun 17, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TARS
Bearish
medium confidence
Mentioned
$TARS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSBearishLow
01

Why it matters

The newest fact is the disclosed open-market sale by an officer (Jeffrey S. Farrow) on 2026-06-16, with holdings after the sale of 56,801 shares.

02

Market read

Traders may briefly reassess sentiment around TARS due to officer selling, but there is no new operational or financial guidance information.

03

What to watch

The filing lacks context on total compensation, prior holdings, and whether other insiders are selling/buying around the same period; traders may overinterpret a single sale.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17; sale dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Tarsus Pharmaceuticals, Inc.

Company-level read

Ticker impact

$TARSBearishMedium confidence
Context

SEC Form 4 shows officer Jeffrey S. Farrow sold 14,396 TARS shares on 2026-06-16 at $60.95/share for ~$877K, no 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless follow-on selling or other news emerges.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides only a routine insider sale size/value and no accompanying company-specific operational or guidance change.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical/financing signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • issuer
    Tarsus Pharmaceuticals, Inc.

    Subject of the SEC Form 4 insider sale disclosure.

  • insider
    Jeffrey S. Farrow

    Officer who sold 14,396 shares on 2026-06-16 at $60.95/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TARS insider trading history →

Related articles

SEP 16
$TARSMed

TARS Reinstated by Barclays -- Rating Upgraded to Overweight

Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.

gurufocus.com2 min
SEP 10
$TARSHighAI 8/10

Tarsus Pharmaceuticals, Inc. (TARS): Completion of Acquisition or Disposition of Assets

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote

SEC EDGAR 8-K2 min
SEP 8
$TARSMed

Jefferies raises Tarsus Pharmaceuticals price target on guidance

Jefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.

investing.com2 min
SEP 4
$TARSMed

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a Phase 3 investigational therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is expected to report topline data in 2029. The acquisition expands Tarsus' pipeline and supports its eye care strategy. TARS shares closed at $83.21 on Thursday, up 0.54%.

rttnews.com2 min
SEP 4
$TARSMed

A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one.

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a late-stage oral therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is in a Phase 3 trial with topline data expected in 2029. Tarsus believes ALK-001 could be a blockbuster treatment for this inherited retinal disease with no FDA-approved therapies.

stocktitan.net2 min